Tolerability of gefitinib in patients receiving treatment in everyday clinical practice
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6601477.pdf
Reference27 articles.
1. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110–124
2. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292–4302
3. BC Cancer Agency (2003) http://www.bccancer.bc.ca.default.htm
4. Bhatia S, Hanna N, Ansari R, Pletcher W, Einhorn L, Ng E, Sandler A (2002) A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 38: 73–77
5. British National Formulary (2003) BNF 46. http://www.bnf.org
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. 3D printing injectable microbeads using a composite liposomal ink for local treatment of peritoneal diseases;Drug Delivery and Translational Research;2023-11-25
2. EGFR is a potential dual molecular target for cancer and Alzheimer’s disease;Frontiers in Pharmacology;2023-08-02
3. Advances in the study of regulators of ferroptosis in head and neck squamous cell carcinoma (Review);International Journal of Molecular Medicine;2023-04-13
4. Epithelial Membrane Protein 1 Promotes Sensitivity to RSL3-Induced Ferroptosis and Intensifies Gefitinib Resistance in Head and Neck Cancer;Oxidative Medicine and Cellular Longevity;2022-04-06
5. Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases;European Journal of Clinical Pharmacology;2020-06-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3